CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...